Safer CARS
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Genetically modifying T cells to express synthetic chimeric antigen receptors (CARs)1Sadelain M Riviere I Brentjens R Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer. 2003; 3: 35-45Crossref PubMed Scopus (408) Google Scholar is an attractive strategy for producing antitumor effects. The first-generation CARs usually consisted of the single-chain variable fragment of an antibody specific for tumor antigen linked to the transmembrane and intracellular signaling domains of either CD3ζ or FcRγ. This produces human leukocyte antigen (HLA)-unrestricted activation of the modified cytotoxic T lymphocytes (CTLs) upon encounter with tumor antigen, leading to lysis of tumor cells in vitro and eradication of tumor in mouse models. Because CARs bind to target antigens in an HLA-unrestricted manner, they are resistant to many tumor-immune evasion mechanisms, such as downregulation of HLA class I molecules or failure to process or present proteins. However, efficacy was modest in clinical trials in subjects with lymphoma, neuroblastoma, or ovarian or renal cancer2Till BG Jensen MC Wang J Chen EY Wood BL Greisman HA et al.Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.Blood. 2008; 112: 2261-2271Crossref PubMed Scopus (566) Google Scholar,3Kershaw MH Westwood JA Parker LL Wang G Eshhar Z Mavroukakis SA et al.A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.Clin Cancer Res. 2006; 12: 6106-6115Crossref PubMed Scopus (934) Google Scholar,4Lamers CH Sleijfer S Vulto AG Kruit WH Kliffen M Debets R et al.Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.J Clin Oncol. 2006; 24: e20-e22Crossref PubMed Scopus (703) Google Scholar because of incomplete activation of T cells with limited expansion and persistence in vivo. Normal T-cell activation is dependent on receipt of two classes of signal: one through the engagement of the T-cell receptor (TCR) with antigen presented in the context of the major histocompatibility complex and a second through engagement of costimulatory molecules such as CD28, OX40, and CD40L. Tumors often do not express appropriate ligands for costimulatory molecules, and engagement of first-generation CARs in the absence of costimulation leads to anergy and failure of in vivo expansion. To overcome these limitations, second-generation CARs were developed to incorporate the intracellular domains of one or more costimulatory molecules such as CD28, OX40, and 4-1BB within the endodomain, and these improved antigen-specific T-cell activation and expansion.1Sadelain M Riviere I Brentjens R Targeting tumours with genetically enhanced T lymphocytes.Nat Rev Cancer. 2003; 3: 35-45Crossref PubMed Scopus (408) Google Scholar,5Maher J Brentjens RJ Gunset G Riviere I Sadelain M Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor.Nat Biotechnol. 2002; 20: 70-75Crossref PubMed Scopus (712) Google Scholar Third-generation CARs include a combination of costimulatory endodomains.6Zhao Y Wang QJ Yang S Kochenderfer JN Zheng Z Zhong X et al.A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.J Immunol. 2009; 183: 5563-5574Crossref PubMed Scopus (240) Google Scholar An alternative approach to providing costimulation is to express CARs in antigen-specific T cells, which will then also be activated and expanded following engagement of their native αβTCR by antigen on professional antigen-presenting cells, with attendant costimulation.7Pule MA Savoldo B Myers GD Rossig C Russell HV Dotti G et al.Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat Med. 2008; 14: 1264-1270Crossref PubMed Scopus (934) Google Scholar,8Cooper LJ Al Kadhimi Z Serrano LM Pfeiffer T Olivares S Castro A et al.Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.Blood. 2005; 105: 1622-1631Crossref PubMed Scopus (95) Google Scholar In a recently reported clinical trial, subjects receiving Epstein-Barr virus (EBV)-specific CTLs engineered with a CAR (CAR-CTLs) specific for the disialoganglioside antigen GD2a on neuroblastoma cells showed longer in vivo persistence than unselected T cells engineered with a distinguishable GD2-CAR, due to stimulation of the CAR-CTLs by EBV antigen.7Pule MA Savoldo B Myers GD Rossig C Russell HV Dotti G et al.Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.Nat Med. 2008; 14: 1264-1270Crossref PubMed Scopus (934) Google Scholar More than 10 clinical trials e
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Cited by
Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering
Billingsley, M. M., Singh, N., Ravikumar, P., Zhang, R., June, C. H., & Mitchell, M. J. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04246 · Cited by 636
Moon, E. K., Carpenito, C., Sun, J., Wang, L.-C. S., Kapoor, V., Predina, J., Powell, D. J., Riley, J. L., June, C. H., & Albelda, S. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0351 · Cited by 537
Wilkie, S., van Schalkwyk, M. C. I., Hobbs, S., Davies, D. M., van der Stegen, S. J. C., Pereira, A. C. P., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9689-9 · Cited by 478
Zhao, Y., Moon, E., Carpenito, C., Paulos, C. M., Liu, X., Brennan, A. L., Chew, A., Carroll, R. G., Scholler, J., Levine, B. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2880 · Cited by 450
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
Jena, B., Dotti, G., & Cooper, L. J. N. (2010) · Blood · doi:10.1182/blood-2010-01-043737 · Cited by 297
Tettamanti, S., Marin, V., Pizzitola, I., Magnani, C. F., Giordano Attianese, G. M. P., Cribioli, E., Maltese, F., Galimberti, S., Lopez, A. F., Biondi, A., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12282 · Cited by 211
Mechanism of Action of Immunotherapy
Disis, M. L. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.004 · Cited by 175
van der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126
Immunotherapy for metastatic solid cancers
Turcotte, S., & Rosenberg, S. A. (2011) · Advances in Surgery · doi:10.1016/j.yasu.2011.04.003 · Cited by 81
Engineered T cells for pancreatic cancer treatment
Katari, U. L., Keirnan, J. M., Worth, A. C., Hodges, S. E., Leen, A. M., Fisher, W. E., & Vera, J. F. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00344.x · Cited by 61
Is cancer gene therapy an empty suit?
Brenner, M. K., Gottschalk, S., Leen, A. M., & Vera, J. F. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70173-6 · Cited by 52
Metadata
- Authors
- Heslop, H. E.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 18
- Issue
- 4
- Pages
- 661-662
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4230689412
- Cited by
- 70
- References
- 1
- FWCI
- 5.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.